Analysis of the Innovative Technology and Economic and Social Benefits of the First Domestic Generic of Rupatadine Fumarate Tablets

This article provides an in-depth analysis of the innovative technology and economic and social benefits of the first domestic generic of rupatadine fumarate tablets. As a novel anti-allergic drug, rupatadine fumarate tablets exhibit a dual-channel inhibitory mechanism by antagonizing both histamine and platelet-activating factor (PAF). In terms of technological innovation, the drug has improved stability and quality control through precise formulation screening and a proprietary compound crystal preparation method. The optimized process reduces the content of related substances, maintaining consistency with the reference product while offering a price advantage. It demonstrates significant clinical efficacy, with good therapeutic effects on allergic rhinitis, urticaria, and other conditions, and exhibits high safety. In terms of market performance, rupatadine fumarate tablets have achieved high coverage and considerable sales in the domestic market, and the generic version further enhances market competitiveness through its pricing strategy. Furthermore, the development and production of this generic drug have brought extensive social benefits, promoting the development of the domestic pharmaceutical industry and stimulating the pharmaceutical supply chain. The first domestic generic of rupatadine fumarate tablets has emerged as a new star in the field of anti-allergy, providing new ideas for pharmaceutical innovation.